Current Edition

Oxford Genetics Supports Significant Growth with New U.S. Office

Company to extend its presence into the U.S. as a key cell and gene therapy market
 12 September, 2017, Oxford – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has announced that it has opened its first U.S. office located at the NGIN workplace near Kendall Square in the Cambridge district of Boston.
By expanding into the U.S. market, the company is well positioned to respond to its existing customers’ needs, while also leveraging the very attractive sector and growing market.
This is the company’s first office outside of the U.K., and will support its rapidly growing business in the U.S. and reinforce its commitment to delivering solutions that improve the discovery and development of biotherapeutics. Oxford Genetics aims to grow its U.S. commercial team to approx. 10 over the next 18 months, build on collaborative partnerships and will focus on driving sales, as well as strengthening its customer and technical support offering.
This global expansion follows the company’s latest successful round of financing in which it secured a £7.5 million investment, that will also support the company’s 6,000-sq. ft. expansion of its U.K. facility at Oxford Science Park. This will include state-of-the-art cell line engineering capabilities, viral vector production and purification suites, high-throughput robotic screening systems and process development facilities.
Paul Brooks, CCO of Oxford Genetics, said: “Over the past twelve months we have seen increasing demand for our technologies and services from the U.S. market so the decision to expand our presence there was a logical step in the growth strategy of our business. The Boston area is a thriving hub for biotechnology talent and technologies which we look forward to being a part of, as well as increasing our ability to service a key growing market for Oxford Genetics.”